Adaptive Biotechnologies and Biogen Idec are together searching for immunological biomarkers for difficult-to-treat autoimmune diseases, the firms said. Financial terms were not disclosed.
Under the terms of the agreement, the firms will use Adaptive’s immune profiling assay immunoSEQ to characterize samples from patients with autoimmune disorders with high unmet needs. The assay uses next-generation sequencing to characterize T and B cell receptors for the purpose of monitoring patient immune status.
“We are delighted to collaborate with Biogen Idec to help further characterize the immune status of patients with autoimmune diseases who are often quite heterogeneous and therefore, difficult to treat without a more personalized approach,” Adaptive CEO Chad Robinssaid in a statement. “Partnering with Biogen Idec fits squarely with Adaptive’s dual commitment to a deeper understanding of complex diseases as well as to finding better means to treat them.”